# A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

> **NCT04742153** · PHASE2 · UNKNOWN · sponsor: **Shanghai Miracogen Inc.** · enrollment: 66 (estimated)

## Conditions studied

- Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** MRG002

## Key facts

- **NCT ID:** NCT04742153
- **Lead sponsor:** Shanghai Miracogen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-13
- **Primary completion:** 2023-02
- **Final completion:** 2023-02
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2022-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04742153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04742153, "A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04742153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*